Careteq (ASX:CTQ) Inventories, Finished Goods: A$0.00 Mil (As of Dec. 2025)


What is Careteq Inventories, Finished Goods?

Careteq ASX:CTQ +8.33% Inventories, Finished Goods is A$0.00 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Careteq's annual finished goods declined from Jun. 2023 (A$0.24 Mil) to Jun. 2024 (A$0.00 Mil) but then stayed the same from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil).

Careteq Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Careteq's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Careteq Inventories, Finished Goods Chart

Careteq Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Inventories, Finished Goods
0.00 0.00 0.24 0.00 0.00

Careteq Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Careteq Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of A$0.00 Mil mean?
Careteq (ASX:CTQ) has a Inventories, Finished Goods of A$0.00 Mil as of Dec. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on Careteq and its competitors.
Is Careteq's Inventories, Finished Goods too high?
Careteq's current Inventories, Finished Goods is A$0.00 Mil.
How does Careteq's Inventories, Finished Goods compare to VEEV and BTSG?
Careteq's Inventories, Finished Goods of A$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Healthcare Providers & Services company?
A good Inventories, Finished Goods depends on the Healthcare Providers & Services industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Careteq and its competitors. Careteq's current Inventories, Finished Goods is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Careteq stock overvalued right now?
Based on GuruFocus' analysis, Careteq (ASX:CTQ) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 30% above its estimated fair value. The current Inventories, Finished Goods is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Careteq (ASX:CTQ), the current Inventories, Finished Goods is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Careteq Business Description

Address 99 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
Careteq Ltd provides Residential Medication Management Review and Home Medicines Review services as part of the Medication Management Programs, generating revenue from medication review, education, and support services. The company focuses on medication management and home care solutions to provide continuity of care and improve clinical outcomes for patients through Home Medication Reviews. Medication-related harm includes adverse drug reactions, medication errors, and complications that jeopardise patient safety and increase healthcare costs. The company operates in Australia.